Therapeutic targeting of respiratory syncytial virus G-protein.
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in infants and young children and an important pathogen of the elderly and immune suppressed. The only intervention currently available is a monoclonal antibody against the RSV fusion protein, which has shown utility as a prophylactic for high-risk premature infants, but which has not shown postinfection therapeutic efficacy in the specific RSV-infected populations studied. Thus, for the major susceptible populations, there remains a great need for effective treatment. Recent results support monoclonal antibody targeting of the RSV G-protein for therapeutic use. This objective encompasses a dual mechanism: reduction in the ability of RSV G-protein to distort the host innate immune response, and direct complement-mediated antiviral activity.
Kauvar
Lawrence M
LM
Trellis Bioscience, 2-B Corporate Drive, South San Francisco, CA 94080, USA. lkauvar@trellisbio.com
Harcourt
Jennifer L
JL
Haynes
Lia M
LM
Tripp
Ralph A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000276:immunology; D006801:Humans; D057131:Immune Evasion / Q000187:drug effects; D007113:Immunity, Innate / Q000187:drug effects; D007167:Immunotherapy; D018357:Respiratory Syncytial Virus Infections / Q000178:diet therapy* / Q000276:immunology; D012136:Respiratory Syncytial Viruses / Q000276:immunology* / Q000472:pathogenicity; D012306:Risk; D014764:Viral Proteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D014764:Viral Proteins; D019204:GTP-Binding Proteins